Ken Griffin Eiger Bio Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Put Options

4 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.21 - $0.43 $42 - $86
200 New
200 $0
Q1 2023

May 15, 2023
SELL
$0.89 - $2.52 $22,873 - $64,764
-25,700 Reduced 65.73%
13,400 $12,000
Q4 2022

Feb 14, 2023
BUY
$1.02 - $7.48 $28,866 - $211,684
28,300 Added 262.04%
39,100 $46,000
Q3 2022

Nov 14, 2022
BUY
$6.04 - $9.66 $65,232 - $104,328
10,800 New
10,800 $81,000

Others Institutions Holding EIGR

# of Institutions
6
Shares Held
748K
Call Options Held
0
Put Options Held
0
View Full List

About Eiger BioPharmaceuticals, Inc.

EIGR Quotes by TradingView
  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $490M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email